PTK2 and cancer: Given the evidence from ongoing clinical trials that a substantial proportion of KRAS G12C mutant cancer patients do not benefit from KRAS inhibition therapy,[33] we explored whether the FAK–YAP axis may explain the resistance to KRAS G12C inhibition.